Wells Messersmith, MD
Enriched profileProfessor of Medicine-Medical Oncology; Division Head, Division of Medical Oncology; Associate Director for Translational/Clinical Research, University of Colorado Cancer Center; Chief Medical Officer of Oncology Services, UCHealth · University of Colorado Cancer Center
Wells Messersmith is Professor of Medicine-Medical Oncology; Division Head, Division of Medical Oncology; Associate Director for Translational/Clinical Research, University of Colorado Cancer Center; Chief Medical Officer of Oncology Services, UCHealth at University of Colorado Cancer Center. OpenAlex indexes 784 publications with 23,739 citations (h-index 70); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Wells Messersmith, MD, is Professor of Medicine-Medical Oncology at University of Colorado Cancer Center / University of Colorado School of Medicine (Anschutz Medical Campus). The public record shows 784 publications with 23,739 citations (h-index 70), centered on Colorectal Cancer, Pancreatic Cancer. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 2 companies, 4 NIH-funded awards (2007–2014).
- Most recent indexed publication: 2025 · Cancer research communications
- Top research focus: Colorectal Cancer
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →criteriuminc.com ↗
- Member
NCI/CTEP Investigational Drug Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Sponsor: University of Colorado, Denver
- A Study of NX-1607 in Adults With Advanced Malignancies
Sponsor: Nurix Therapeutics, Inc.
Industry payments
Updated 27 Aug 2026
2 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20248 payments
- Amgen Inc.Program year20234 payments
- Amgen Inc.Program year20224 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
38.8%Opioid Agonist16.5%Fentanyl100%Part D<11 patientsPhenothiazine11.6%Prochlorperazine Maleate100%Part D<11 patientsCancer & immunology
34.7%Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors14.9%Fruzaqla100%Part D<11 patientsKinase inhibitor10.7%Everolimus100%Part D<11 patientsMetabolism & gastrointestinal
16.5%Serotonin-3 Receptor Antagonist16.5%Ondansetron Hcl100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2007–2014 per NIH RePORTER. The latest:
- The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
Johns Hopkins University
FY2026$1,854,447UM1CA186691 - The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
Johns Hopkins University
FY2025$1,817,609UM1CA186691 - The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
Johns Hopkins University
FY2024$1,727,315UM1CA186691
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.
Cancer research communications
Clinical Trial2025 - Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer.
JCO oncology practice
Article2025 - A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Clinical cancer research
Clinical Trial2024 - A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer.
Clinical cancer research
Clinical Trial2024
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/scientific-contributions/Wells-A-Messersmith-39387735
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
society.asco.org/people/wells-a-messersmith-md-facp
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →society.asco.org ↗ - X / Twitter
x.com/SunnieSKim/status/1883280314598035857
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Editorial & leadership roles
journal and society appointments- Division Head
Division of Medical Oncology, University of Colorado School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.cuanschutz.edu ↗
- Associate Director for Translational/Clinical Research
University of Colorado Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Secondary affiliations
appointments beyond the home institution- Director
Academic GI Cancer Consortium (AGICC), a Criterium-operated multi-institutional oncology CRO consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →criteriuminc.com ↗
Media & interviews
press, podcasts and appearances- PharmaVoice/Criterium One-on-One video interview
discussing AGICC and GI cancer drug development
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →9news.com ↗
- Recurring video contributor/author on OncLive discussing colorectal cancer treatment
HER2-targeted therapy, and biomarkers
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bryan Haugen, MD
University of Colorado Cancer Center
Thomas Flaig, MD
University of Colorado Cancer Center
Christopher Lieu, MD
University of Colorado Cancer Center
Ritu Salani, MD
University of Colorado Cancer Center